| Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer M Reck, D Rodríguez-Abreu, AG Robinson, R Hui, T Csőszi, A Fülöp, ... New England Journal of Medicine 375 (19), 1823-1833, 2016 | 8378 | 2016 |
| Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer AT Shaw, DW Kim, K Nakagawa, T Seto, L Crinó, MJ Ahn, T De Pas, ... New England Journal of Medicine 368 (25), 2385-2394, 2013 | 3858 | 2013 |
| Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer JC Soria, Y Ohe, J Vansteenkiste, T Reungwetwattana, B Chewaskulyong, ... New England journal of medicine 378 (2), 113-125, 2018 | 3761 | 2018 |
| Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations LV Sequist, JCH Yang, N Yamamoto, K O'Byrne, V Hirsh, T Mok, ... Journal of clinical oncology 31 (27), 3327-3334, 2013 | 3491 | 2013 |
| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 3473 | 2017 |
| Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ... New England Journal of Medicine 376 (7), 629-640, 2017 | 3006 | 2017 |
| Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC MA Socinski, RM Jotte, F Cappuzzo, F Orlandi, D Stroyakovskiy, ... New England Journal of Medicine 378 (24), 2288-2301, 2018 | 2906 | 2018 |
| Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden MD Hellmann, TE Ciuleanu, A Pluzanski, JS Lee, GA Otterson, ... New England Journal of Medicine 378 (22), 2093-2104, 2018 | 2637 | 2018 |
| First-line nivolumab in stage IV or recurrent non–small-cell lung cancer DP Carbone, M Reck, L Paz-Ares, B Creelan, L Horn, M Steins, E Felip, ... New England Journal of Medicine 376 (25), 2415-2426, 2017 | 2285 | 2017 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2278 | 2018 |
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2–positive metastatic breast … M Marty, F Cognetti, D Maraninchi, R Snyder, L Mauriac, M Tubiana-Hulin, ... Journal of clinical oncology 23 (19), 4265-4274, 2005 | 1948 | 2005 |
| Nivolumab plus ipilimumab in advanced non–small-cell lung cancer MD Hellmann, L Paz-Ares, R Bernabe Caro, B Zurawski, SW Kim, ... New England Journal of Medicine 381 (21), 2020-2031, 2019 | 1841 | 2019 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial R Pirker, JR Pereira, A Szczesna, J von Pawel, M Krzakowski, R Ramlau, ... The Lancet 373 (9674), 1525-1531, 2009 | 1771 | 2009 |
| Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC SS Ramalingam, J Vansteenkiste, D Planchard, BC Cho, JE Gray, Y Ohe, ... New England Journal of Medicine 382 (1), 41-50, 2020 | 1631 | 2020 |
| Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised … JCH Yang, YL Wu, M Schuler, M Sebastian, S Popat, N Yamamoto, ... The lancet oncology 16 (2), 141-151, 2015 | 1625 | 2015 |
| Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled … K Park, EH Tan, K O'Byrne, L Zhang, M Boyer, T Mok, V Hirsh, JCH Yang, ... The Lancet Oncology 17 (5), 577-589, 2016 | 1113 | 2016 |
| Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung Cancer YL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ... New England journal of medicine 383 (18), 1711-1723, 2020 | 1039 | 2020 |
| Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor … B Morgan, AL Thomas, J Drevs, J Hennig, M Buchert, A Jivan, ... Journal of Clinical Oncology 21 (21), 3955-3964, 2003 | 740 | 2003 |
| Chronic immune activation and inflammation as the cause of malignancy KJ O'Byrne, AG Dalgleish British journal of cancer 85 (4), 473-483, 2001 | 728 | 2001 |
| Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery … T Treasure, L Lang-Lazdunski, D Waller, JM Bliss, C Tan, J Entwisle, ... The lancet oncology 12 (8), 763-772, 2011 | 727 | 2011 |
